H19 inhibition reversed MCAO injury worsened by miR-29b antagomir
To further elucidate the relationships among H19, miR-29b, and C1QTNF6 in cerebral ischemic injury, we intravenously injected H19 siRNA in MCAO rats with miR-29b antagomir and analysed the infarct volume and brain oedema at 24 h after MCAO. H19 siRNA reduced cerebral infarct volume and brain oedema compared with that in MCAO rats treated with miR-29b antagomir (Figure 4A,P < 0.05). Additionally, H19 siRNA significantly improved neurological deficits in MCAO rats with miR-29b antagomir treatment (Figure 4A, P < 0.05).
C1QTNF6 mRNA and proteins in leukocytes and the brain, respectively, were significantly higher in MCAO rats treated with miR-29b antagomir than in MCAO rats. Moreover, this increase was downregulated by H19 siRNA treatment (Figure 4C, D, P < 0.05). Additionally, cerebral and leukocyte TNF-α levels, as well as IL-1β levels, were decreased in rats treated with H19 siRNA than in MCAO rats treated with miR-29b antagomir (Figure 4C, D, P < 0.05). These findings suggest that H19 promotes TNF-α and IL-1β secretion by targeting the miR-29b/C1QTNF6 axis in leukocytes.
H19 and miR-29b in HL-60 cells regulate hCMEC/D3